Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Go back to Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer| AGENUS (NASDAQ: AGEN) | Delayed: 7.43 -0.81 (9.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.24 | 52 Week High | $7.49 | |||
| Open | $8.14 | 52 Week Low | $2.61 | |||
| Day High | $8.18 | P/E | N/A | |||
| Day Low | $7.42 | EPS | $-1.10 | |||
| Volume | 1,207,565 | |||||
